我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

急性心肌梗死患者早期不同剂量阿托伐他汀对hs-CRP、血脂水平的影响

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2015年第3期
页码:
307-309
栏目:
临床研究
出版日期:
2015-01-11

文章信息/Info

Title:
Effect of early use of atorvastatin on hs-CRP and blood lipid levels in patients with acute myocardial infarction
作者:
张振岭1; 马 丽2; 任 澎2
（1.石河子大学医学院，新疆 石河子 832003；
2.新疆自治区人民医院心内科，新疆 乌鲁木齐 830000）
Author(s):
ZHANG Zhen-ling1;  MA Li2;  REN Peng2
(1.Medicine of Shihezi University, Shihezi 832003, Xinjiang, China；
2.Department of Cardiology, People’s Hospital, Xinjiang Autonomous Region, Urumqi 830000, Xinjiang, China)
关键词:
心肌梗死; 急性; 阿托伐他汀; 超敏C反应蛋白; 血脂水平
Keywords:
acute myocardial infarction;  atorvastatin;  hypersensitive C-reactive protein;  lipid levels
分类号:
R329.2；R541.4
DOI:
-
文献标识码:
A
摘要:
目的:探讨不同剂量阿托伐他汀治疗对急性心肌梗死（AMI）患者早期超敏C反应蛋白(hs-CRP)、血脂水平的影响。方法:选取2014年1月~5月入院确诊的AMI患者60例，随机分为20 mg组和40 mg组，每组30例，所有患者入院后均在常规治疗的基础上加用阿托伐他汀，分别给予20 mg和40 mg。比较两组患者入院时和治疗l周后不同剂量对血清hs-CRP、血脂水平的影响。结果:两组治疗前后1周血清hs-CRP、总胆固醇、低密度脂蛋白胆固醇（LDL-C）及高密度脂蛋白胆固醇水平均较入院时显著下降，且40 mg组较20 mg组治疗后LDL-C水平显著下降,两组间差异有统计学意义（P<0.05）。结论:AMI患者早期（1周内）阿托伐他汀治疗对降低hs-CRP、血脂水平有效，并且40 mg组在LDL-C降低幅度上优于20 mg组。
Abstract:
AIM:To explore the effect of different doses atorvastatin treatment on the levels of serum hypersensitive C-reactive protein (CRP) and lipid in patients who were in early acute myocardial infarction (AMI). METHODS: A total of 60 patients with AMI who were hospitalized from January 2014 to May 2014 were randomly divided into 20 mg and 40 mg groups with 30 patients in each group. All patients were administered atorvastatin on the basis of conventional treatment after admission, 20 mg and 40 mg, respectively. We compared the effect on the levels of hs-CRP and lipids in patients of both groups upon hospital admission and after treatment for 1 week with different doses of atorvastatin. RESULTS: Levels of serum hs-CRP, total cholesterol, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol in the two groups before and after 1 week treatment were decreased significantly, and the level of LDL-C decreased more significantly in the 40 mg group than in the 20 mg group after treatment, with statistically significant differences between groups (P<0.05). CONCLUSION: Atorvastatin therapy may reduce levels of serum hs-CRP and lipid effectively in early AMI patients (within 1 week), and the reduction of LDL-C in the 40 mg group is more significant than in the 20 mg group.

参考文献/References

[1]袁 月,王 艳.阿托伐他汀对急性心肌梗死患者C反应蛋白及血脂的影响[J].四川医学,2009,30(8):1265-1267.
[2]尹建国,姜德谦,张社兵.不同剂量阿托伐他汀对急性心肌梗死患者血清淀粉样蛋白A、超敏C反应蛋白的影响[J].临床荟萃,2011,26(24):2177-2178.
[3]朱继红,汪砚雨.阿托伐他汀治疗老年急性心肌梗死患者的疗效及对血脂水平的影响[J].中国老年学杂志,2012,32(8):1582-1584.
[4]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高性心肌梗死诊断和治疗指南[J].中华心血管病杂志,2010,38(8):675.
[5]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高的急性冠脉综合征诊断和治疗指南[J].中华心血管病杂志,2012,40(5):353.
[6]European Association for Cardiovascular Prevention & Rehabilitation,Reiner Z,Catapano AL,et al.ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS)[J].Eur Heart J,2011,32(14):1769-1818.
[7]霍 勇,葛均波,韩雅玲,等.急性冠状动脉综合征患者强化他汀治疗专家共识[J].中国介入心脏病学杂志,2014,22(1):4-6.
[8]Ostadal P,Alan D,Hajek P,et al.The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction[J].Mol Cell Biochem, 2003,246(1/2):45-50.
[9]刘 健,王 昭,王伟民.2012欧洲ST段抬高急性心肌梗死患者管理指南解读[J].中国医学前沿杂志(电子版),2013,5(2):55-60.
[10]De Luca G,Navarese EP,Cassetti E,et al.Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy[J].Am J Cardiol,2011,107(2):198-203.
[11]Gore JM,Goldberg RJ,Matstaxioto AS,et al.Validity of serum to-tal cholesterol level obtained within 24 hours of acute myocardial in-farction[J].Am J Cardiol,1984,54(7):722-725.
[12]Vaisar T,Pennathur S,Green S,et al.Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL[J].J Clin Invest,2007,117(3):746-756.
[13]Kotseva K,Wood D,De Backer G,et al.EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries[J].Eur J Cardiovasc Prev Rehabil,2009,16(2):121-137.

备注/Memo

备注/Memo:
收稿日期：2014-07-08.
通讯作者：任澎，主任医师，主要从事冠心病的基础与临床研究Email:RenPengcvd@126.com
作者简介：张振岭，硕士生Email：zhang_zhen_ling@163.com
更新日期/Last Update: 2015-02-03